Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Endocrinology

Background:

• Metabolic reprogramming is a hallmark of cancer, enabling adaptation and growth.
• Hormone receptor-positive (HR+) breast cancers constitute ~70% of cases and exhibit metabolic dependencies.
• Nuclear receptors, including hormone-dependent signaling, are implicated in driving metabolic alterations in HR+ breast cancer.

Purpose of the Study:

• To review the mechanisms of hormone receptor-mediated metabolic reprogramming in HR+ breast cancer.
• To discuss the impact of these metabolic changes on cancer genesis and progression.
• To explore the therapeutic implications of targeting metabolic processes in HR+ breast cancer.

Main Methods:

• Literature review of studies on cancer metabolism and HR+ breast cancer.
• Analysis of signaling pathways involving nuclear receptors and metabolic enzymes.
• Synthesis of current understanding of metabolic reprogramming in HR+ breast cancer.

Main Results:

• Hormone receptor signaling significantly influences metabolic pathways crucial for HR+ breast cancer.
• Altered metabolism supports tumor growth, metastasis, and resistance to therapy in HR+ breast cancer.
• Targeting these metabolic vulnerabilities presents potential therapeutic strategies.

Conclusions:

• Metabolic reprogramming, particularly driven by hormone receptors, is central to HR+ breast cancer progression.
• Understanding these mechanisms is vital for developing novel therapeutic interventions.
• Targeting metabolic pathways offers a promising avenue for treating HR+ breast cancer.